Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$16.53 - $21.42 $8,331 - $10,795
504 Added 0.33%
154,824 $3.29 Million
Q3 2023

Nov 09, 2023

SELL
$20.08 - $25.39 $20,300 - $25,669
-1,011 Reduced 0.65%
154,320 $3.11 Million
Q2 2023

Aug 11, 2023

BUY
$24.77 - $29.9 $16,026 - $19,345
647 Added 0.42%
155,331 $3.88 Million
Q1 2023

May 15, 2023

BUY
$25.95 - $36.95 $49,616 - $70,648
1,912 Added 1.25%
154,684 $4.31 Million
Q4 2022

Feb 14, 2023

BUY
$24.79 - $30.86 $3.79 Million - $4.71 Million
152,772 New
152,772 $3.98 Million
Q3 2022

Nov 14, 2022

BUY
$24.62 - $32.44 $3.5 Million - $4.61 Million
142,202 New
142,202 $3.7 Million
Q2 2022

Aug 15, 2022

BUY
$19.74 - $29.01 $813,880 - $1.2 Million
41,230 Added 41.87%
139,691 $3.82 Million
Q1 2022

May 13, 2022

BUY
$26.68 - $41.63 $6,616 - $10,324
248 Added 0.25%
98,461 $2.63 Million
Q4 2021

Feb 14, 2022

BUY
$33.67 - $43.44 $153,434 - $197,956
4,557 Added 4.87%
98,213 $3.94 Million
Q3 2021

Nov 03, 2021

BUY
$30.65 - $35.68 $76,103 - $88,593
2,483 Added 2.72%
93,656 $3.06 Million
Q2 2021

Aug 12, 2021

SELL
$34.33 - $44.68 $399,223 - $519,583
-11,629 Reduced 11.31%
91,173 $3.14 Million
Q1 2021

May 13, 2021

BUY
$40.81 - $53.88 $639,615 - $844,461
15,673 Added 17.99%
102,802 $4.43 Million
Q4 2020

Feb 12, 2021

SELL
$36.63 - $47.63 $59,120 - $76,874
-1,614 Reduced 1.82%
87,129 $3.8 Million
Q3 2020

Nov 13, 2020

BUY
$30.09 - $43.02 $1.93 Million - $2.76 Million
64,221 Added 261.89%
88,743 $3.44 Million
Q2 2020

Aug 14, 2020

BUY
$27.76 - $33.42 $680,730 - $819,525
24,522 New
24,522 $794,000

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.09B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Segall Bryant & Hamill, LLC Portfolio

Follow Segall Bryant & Hamill, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.